Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs (Form 8-K)

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Aliso Viejo, CA, July 6th, 2026 - Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

Under the collaboration, the companies will be innovating on their respective platforms - RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs - and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.

"Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery," said David J. Endicott, Chief Executive Officer of Alcon. "Together with RxSight's technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery."

"We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery," said Ron Kurtz, President and Chief Executive Officer of RxSight. "This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients."

As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

RxSight, Inc. | 100 Columbia, Aliso Viejo, CA 92656 | rxsight.com

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.